Capricor's Deramiocel Shows Statistically Significant Upper Limb Function Improvement in DMD Phase 3 Trial
Event summary
- Capricor presented Phase 3 HOPE-3 trial results for Deramiocel in Duchenne muscular dystrophy (DMD) at the AAN 2026 Annual Meeting on April 21, 2026.
- The trial demonstrated statistically and clinically meaningful improvements in upper limb function, measured by Performance of the Upper Limb (PUL v2.0) and Duchenne Video Assessment (DVA).
- Deramiocel is under FDA review with a PDUFA target action date of August 22, 2026.
- Capricor has partnerships with Nippon Shinyaku Co., Ltd. for exclusive commercialization in the U.S. and Japan, subject to regulatory approval.
The big picture
Capricor's positive Phase 3 trial results for Deramiocel mark a significant milestone in the treatment of Duchenne muscular dystrophy, a rare and debilitating disease with limited therapeutic options. The data position Deramiocel as a potentially transformative therapy, addressing a critical unmet need in the DMD community. The strategic partnerships with Nippon Shinyaku and the regulatory designations underscore the company's commitment to bringing this therapy to market swiftly.
What we're watching
- Regulatory Approval
- Whether the FDA will approve Deramiocel by the PDUFA target action date of August 22, 2026, given the positive Phase 3 trial results.
- Commercialization Strategy
- How Capricor and Nippon Shinyaku will execute the commercialization strategy for Deramiocel in the U.S. and Japan post-approval.
- Market Impact
- The potential market impact of Deramiocel on the treatment landscape for DMD, considering its Orphan Drug, RMAT, and Rare Pediatric Disease designations.
Related topics